Published in Drug Week, February 10th, 2006
Huntington disease is a hereditary neurodegenerative disorder with large unmet medical needs. ACR16 is a novel dopaminergic stabilizer with potential to treat the symptoms associated with the disorder. It is currently in phase II clinical trials.
Orphan drug status is granted by the OOPD to promote development of drugs to treat rare diseases or conditions. Orphan drug designation in the U.S. may provide several benefits, including protocol...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.